CanariaBio Participates in 'BIOPHARM America'
[Asia Economy Reporter Jang Hyowon] Canaria Bio announced on the 4th that it will participate in BIOPHARM America, held online in a non-face-to-face format until the 5th, to discuss strategic partnerships with global pharmaceutical companies.
Nahanik, CEO of Canaria Bio, stated, “At this event, we plan to introduce the company’s key pipelines such as ovarian cancer, pancreatic cancer, and metastatic breast cancer, and seek strategic partnerships with global pharmaceutical companies.”
Hot Picks Today
!["Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]](https://cwcontent.asiae.co.kr/asiaresize/93/2026040911235619562_1775701437.jpg)
"Target Price Set at 970,000 Won"... Top Investors Already Watching, Only an 'Uptrend' Remains [Weekend Money]
- "Not Everyone Can Afford This: Inside the World of the True Top 0.1% [Luxury World]"
- "Plunged During the War, Now Surging Again"... The Real Reason Behind the 6% One-Day Silver Market Rally [Weekend Money]
- While Everyone Focused on Samsung and Nix, This Company Soared 50%... Hit Record Highs for 4 Days [Weekend Money]
- "They Say They Can't Find Jobs, but They Just Don't Want to Work"... 2030s React Strongly to Dongmin Jang's Criticism
Meanwhile, Oregobomab, the core pipeline for which Canaria Bio is conducting global Phase 3 clinical trials, is a new drug that showed encouraging results in Phase 2 clinical trials targeting newly diagnosed ovarian cancer patients, with progression-free survival (PFS) extended by 30 months compared to the existing standard treatment, reaching 42 months. In addition, another pipeline, Bravarex, a pancreatic cancer treatment, is preparing for Phase 2 clinical trials.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
